Renaissance Technologies LLC Buys 6,300 Shares of Krystal Biotech, Inc. $KRYS

Posted by Francis Steltz on Aug 10th, 2026

Renaissance Technologies LLC lifted its position in Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) by 190.9% during the first quarter, HoldingsChannel.com reports. The fund owned 9,600 shares of the company’s stock after purchasing an additional 6,300 shares during the period. Renaissance Technologies LLC’s holdings in Krystal Biotech were worth $2,480,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Soleus Capital Management L.P. increased its stake in Krystal Biotech by 108.9% in the second quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company’s stock valued at $126,870,000 after purchasing an additional 481,200 shares in the last quarter. Norges Bank bought a new position in shares of Krystal Biotech during the fourth quarter worth $70,159,000. William Blair Investment Management LLC boosted its position in shares of Krystal Biotech by 152.1% during the fourth quarter. William Blair Investment Management LLC now owns 376,340 shares of the company’s stock worth $92,783,000 after purchasing an additional 227,038 shares in the last quarter. Janus Henderson Group PLC grew its holdings in shares of Krystal Biotech by 2,078.9% in the 4th quarter. Janus Henderson Group PLC now owns 219,440 shares of the company’s stock valued at $54,147,000 after buying an additional 209,369 shares during the period. Finally, UBS Group AG increased its position in shares of Krystal Biotech by 970.8% in the 4th quarter. UBS Group AG now owns 159,595 shares of the company’s stock valued at $39,347,000 after buying an additional 177,922 shares in the last quarter. Institutional investors own 86.29% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently commented on KRYS shares. Bank of America raised their price objective on Krystal Biotech from $364.00 to $396.00 and gave the stock a “buy” rating in a research note on Tuesday, July 14th. Evercore restated an “outperform” rating and issued a $300.00 price target on shares of Krystal Biotech in a report on Tuesday, May 5th. HC Wainwright raised their price target on Krystal Biotech from $310.00 to $361.00 and gave the stock a “buy” rating in a research report on Tuesday, June 16th. Citigroup lifted their price objective on Krystal Biotech from $378.00 to $386.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. Finally, TD Cowen boosted their price objective on Krystal Biotech from $306.00 to $403.00 and gave the company a “buy” rating in a research report on Thursday, June 18th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Krystal Biotech has a consensus rating of “Moderate Buy” and an average price target of $361.56.

Read Our Latest Research Report on KRYS

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $308.11, for a total value of $7,702,750.00. Following the sale, the insider owned 1,378,155 shares in the company, valued at approximately $424,623,337.05. The trade was a 1.78% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP John Charles Thomas sold 1,000 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $347.27, for a total value of $347,270.00. Following the transaction, the executive vice president directly owned 1,000 shares of the company’s stock, valued at approximately $347,270. This trade represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 26,642 shares of company stock worth $8,243,923 in the last 90 days. Company insiders own 13.10% of the company’s stock.

Krystal Biotech Price Performance

KRYS opened at $326.45 on Monday. The business’s 50-day moving average price is $341.38 and its two-hundred day moving average price is $297.69. Krystal Biotech, Inc. has a 1 year low of $133.00 and a 1 year high of $382.54. The company has a market capitalization of $9.66 billion, a price-to-earnings ratio of 40.91 and a beta of 0.53.

Krystal Biotech (NASDAQ:KRYS – Get Free Report) last issued its quarterly earnings results on Monday, August 3rd. The company reported $1.79 EPS for the quarter, beating analysts’ consensus estimates of $1.70 by $0.09. The company had revenue of $119.22 million for the quarter, compared to analyst estimates of $120.93 million. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%. Sell-side analysts anticipate that Krystal Biotech, Inc. will post 7.68 earnings per share for the current fiscal year.

Krystal Biotech Profile

(Free Report)

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.